10-K: CytoDyn Reports Net Income Driven by Legal Settlement, Pivots to Oncology Amidst Going Concern Warning

CytoDyn Inc. announced a net income of $3.7 million for fiscal year 2025, primarily due to a $25.0 million legal settlement, as it refocuses its clinical development on solid-tumor oncology while facing significant liquidity challenges and ongoing regulatory investigations.

Summary

• CytoDyn Inc. is a clinical-stage biotechnology company focused on the development of leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.
• The company's current business strategy centers on the clinical development of leronlimab for solid-tumor oncology, specifically continuing a Phase II trial in relapsed/refractory micro-satellite stable colorectal cancer (mCRC) and exploring metastatic Triple-Negative Breast Cancer (mTNBC).
• A new or modified long-acting version of leronlimab is under research and development, leveraging generative AI drug discovery tools.
• For the fiscal year ended May 31, 2025, the company reported a net income of $3.7 million, a significant improvement from a net loss of $49.8 million in fiscal year 2024.
• This net income was primarily attributed to a $25.0 million recovery of clinical expenses resulting from the settlement of litigation with its former Contract Research Organization (CRO), Amarex Clinical Research LLC.
• Cash and cash equivalents increased to $11.9 million as of May 31, 2025, from $3.1 million on May 31, 2024.
• The company continues to face substantial financial challenges, including a significant working capital deficiency and an accumulated deficit of $887.8 million as of May 31, 2025.
• Auditors issued a 'going concern' opinion, indicating substantial doubt about the company's ability to continue operations without securing significant additional funding.
• Short-term liabilities totaled approximately $70.5 million as of May 31, 2025, including $45.4 million in convertible notes and accrued interest, and $16.9 million in accounts payable and accrued liabilities.
• The company's common stock traded at $0.27 per share on June 30, 2025, with a market value of voting and non-voting common equity held by non-affiliates at $134.52 million as of November 30, 2024.

Sentiment

Score: 3

Explanation: While the company reported a net income due to a one-time legal settlement and presented some encouraging early clinical data and a clear strategic pivot to oncology, it faces severe liquidity issues, a 'going concern' audit opinion, ongoing legal and regulatory challenges, and a history of significant operating losses. The ability to continue operations is highly dependent on securing substantial additional financing, which is challenging given the low stock price and existing debt obligations.

Positives

• Achieved a net income of $3.7 million for fiscal year 2025, primarily due to a $25.0 million legal settlement with former CRO, Amarex.
• Cash and cash equivalents increased to $11.9 million as of May 31, 2025, from $3.1 million in May 2024.
• Successfully resolved a dispute with Amarex Clinical Research LLC on favorable terms, including a $12.0 million payment to the company and crediting of $14.0 million in claimed services.
• Received FDA clearance in November 2024 to commence its Phase II colorectal cancer (CRC) trial, signaling an improved relationship with the FDA.
• The first patient was dosed in the Phase II CRC trial in June 2025, with patient enrollment and additional clinical site initiations underway.
• Encouraging historical clinical findings for leronlimab in advanced metastatic colorectal cancer (mCRC) showed three of five patients achieving at least a partial response, including one complete response patient alive five years later.
• Observed survival rates for metastatic Triple-Negative Breast Cancer (mTNBC) patients treated with leronlimab in 2019 trials compare favorably with reported life expectancy from currently approved therapies.
• New data suggests leronlimab treatment correlated with increased PD-L1 expression on circulating tumor cells (CTCs) in mTNBC patients (88% of 17 patients at 525 mg or higher dose), potentially enhancing responsiveness to immune checkpoint inhibitors (ICIs).
• All five mTNBC patients (100%) who demonstrated a significant increase in PD-L1 expression after receiving leronlimab and subsequently received ICI treatment remain alive today.
• An active joint development agreement is in progress to develop a longer-acting CCR5 antagonist using generative AI, which could lead to less frequent injections and extended intellectual property protection.
• Established processes for assessing, identifying, and managing cybersecurity risks, including physical, procedural, and technical safeguards, regular system tests, and employee training.

Negatives

• The reported net income for fiscal year 2025 is primarily due to a non-recurring legal settlement, masking continued underlying operational losses.
• Auditors issued a 'going concern' opinion, indicating substantial doubt about the company's ability to continue operations without significant additional funding.
• Maintains low cash reserves ($11.9 million as of May 31, 2025) and significant short-term liabilities ($70.5 million), including $45.4 million in convertible notes and accrued interest.
• Continued reliance on debt and equity financing has caused and is expected to cause further dilution to existing stockholders.
• The low trading price of common stock ($0.27 per share on June 30, 2025) presents a significant challenge for raising additional funds.
• Pre-launch inventories of leronlimab and related raw materials have been fully written off, and their usability for future development is uncertain.
• Faces difficulty and expense in recruiting and retaining skilled directors, executives, employees, and consultants due to intense competition and limited financial resources.
• Dependent on a limited number of internal research and development personnel, relying heavily on third-party Contract Research Organizations (CROs) and manufacturers, which introduces operational risks.
• Ongoing legal proceedings, including securities class-action lawsuits and shareholder derivative lawsuits, are costly, time-consuming, and divert management focus.
• Subject to SEC and DOJ investigations, which have resulted in criminal convictions of former executives, posing significant reputational and financial risks with unpredictable outcomes.
• Obligations under existing license agreements (e.g., with Progenics, AbbVie, Lonza) require significant milestone, royalty, and license payments upon regulatory approvals and commercialization, which will necessitate additional financing and reduce future revenues.
• Failure to make timely payments under license agreements could trigger repurchase or termination rights for leronlimab.
• An accumulated deficit of $887.8 million as of May 31, 2025, legally prohibits the company from paying any dividends.
• Common stock is classified as 'penny stock,' which may restrict trading activity and limit marketability.
• The trading price of common stock has been and could remain highly volatile.

Risks

• Low cash reserves and the inability to raise substantial additional financing on acceptable terms could force delays, reductions in scope, or cessation of planned operating activities.
• A history of significant operating losses and the expectation to continue incurring them, with no assurance of achieving profitability.
• Future cash requirements may differ significantly from current estimates, depending on factors like strategic partnerships, convertible note conversions, and warrant/option exercises.
• The auditors' 'going concern' opinion raises substantial doubt about the company's ability to continue as an ongoing business.
• Inability to use written-off pre-launch inventories of leronlimab may necessitate engaging third parties to produce additional clinical supplies.
• Difficulty and expense in recruiting and retaining skilled directors, executives, employees, and consultants, potentially adversely affecting drug development and commercialization activities.
• The loss or transition of members of the senior management team or other key employees could adversely affect the business.
• Failure to maintain an effective system of internal control over financial reporting could lead to inaccurate or untimely financial reporting and adversely affect stock price.
• Information technology systems failures, data corruption, cyber-based attacks, or network security breaches could disrupt operations, lead to financial loss, intellectual property loss, reputational harm, and regulatory fines.
• Litigation and other demands made by stockholders, including class-action and derivative lawsuits, could negatively affect business, operating results, and financial condition, with insurance coverage potentially insufficient.
• Oversight by the SEC, FDA, and other regulatory agencies, including ongoing investigations and proceedings, may divert management's focus and have a material adverse effect on reputation and financial condition.
• Agreements with Progenics, AbbVie, and Lonza require significant milestone, royalty, and other payments, which will necessitate additional financing and decrease future revenues; failure to pay could trigger repurchase or termination rights.
• Inability to obtain all required regulatory approvals for leronlimab would prevent commercialization and materially and adversely affect the business, financial condition, and stock price.
• Disruptions at the FDA and other government agencies due to funding shortages, Executive Orders, or global health concerns could hinder product development, approval, or commercialization.
• Dependence on the success of leronlimab; failure to complete clinical development, obtain and maintain marketing approval, or successfully commercialize it would harm the business.
• Competitors may develop drugs that are more effective, safer, or less expensive than leronlimab, or commercialize competing drugs sooner.
• Inability to identify, negotiate, and maintain strategic alliances necessary to develop and commercialize products, or dependence on corporate partners who may fail to perform as expected.
• Known third-party patent rights could delay or adversely affect the planned development and sale of leronlimab, potentially leading to costly infringement suits.
• Reliance on third parties, such as CROs and manufacturers, to conduct clinical trials and produce supplies; their failure to perform or meet regulatory requirements could result in inability to obtain regulatory approvals.
• Uncertainty in obtaining and maintaining intellectual property protection relating to product candidates.
• Potential disputes with contract partners over intellectual property ownership or other matters.
• Common stock is classified as 'penny stock,' which may restrict trading and limit marketability.
• The trading price of common stock has been and could remain volatile, potentially causing investment losses.
• Debt service obligations and the need for additional funding to finance operations will cause additional dilution to existing stockholders and could adversely affect the trading price of common stock.
• The Board's ability to create new series of preferred stock without further stockholder approval could adversely affect the rights of common stockholders.
• Anti-takeover provisions in the certificate of incorporation, bylaws, and Delaware law could make an acquisition more difficult and prevent attempts by stockholders to replace management.
• No expectation of paying cash dividends on common shares in the foreseeable future.

Future Outlook

The company plans to continue the clinical development of leronlimab, focusing on its Phase II trial for relapsed/refractory micro-satellite stable colorectal cancer and exploring additional solid-tumor oncology indications, including metastatic Triple-Negative Breast Cancer. It intends to prospectively confirm retrospective observations in mTNBC and initiate a study on an abbreviated timeline. The company is also actively developing a new or modified long-acting version of leronlimab using generative AI. Significant additional funding will be required to execute this strategy, with plans to pursue both traditional fundraising (equity/debt offerings) and non-dilutive opportunities like licensing and strategic partnerships. The company expects to incur significant research and development expenses related to regulatory compliance and clinical studies.

Management Comments

• "The Company is currently in the process of resuming its clinical development in mTNBC, with the intention to prospectively confirm the retrospective observations in mTNBC outlined above."
• "In the interim, ongoing discussions with KOLs are being conducted towards initiating a study in patients with mTNBC on an abbreviated timeline."
• "The Company believes this collaboration [with generative AI drug discovery company] will result in the expedited development of a modified, longer-acting therapeutic, and could lead to greater acceptance by patients due to the requirement for less frequent injections."
• "Working with a company with established AI-capabilities allows for a robust development path for this modified, longer-acting therapeutic for the Company."
• "Management's assessment of the processes the Company has put in place, does not believe there are currently any known risks from cybersecurity threats that are reasonably likely to materially affect us or our business strategy, results of operations, or financial condition."

Industry Context

CytoDyn operates in the highly competitive biopharmaceutical industry, with a strategic pivot towards oncology and immunology, areas characterized by frequent advancements and high R&D investment. Leronlimab's unique CCR5 targeting mechanism, acting as a competitive rather than allosteric inhibitor, differentiates it from other CCR5 antagonists. The company's focus on metastatic disease aligns with the critical unmet need in cancer treatment, as metastasis is the primary cause of death. The strategy to enhance PD-L1 expression to 'turn cold tumors hot' for immune checkpoint inhibitors positions leronlimab as a potential combination therapy, tapping into a significant and growing area of oncology. However, as a clinical-stage biotech without commercialized products, CytoDyn's financial challenges, including a 'going concern' opinion and reliance on external financing, are common for companies at this stage, highlighting the capital-intensive nature and inherent risks of drug development.

Comparison to Industry Standards

• Observed survival rates for mTNBC patients treated with leronlimab compare favorably with reported life expectancy after treatment with currently approved therapies, though specific comparable therapies or companies are not named.
• The company's focus on metastatic disease, rather than just primary tumors, addresses the leading cause of death in most cancer patients, differentiating its approach from many current therapies.
• Leronlimab's unique mechanism as a competitive CCR5 inhibitor, not activating immune function through agonist activity, differentiates it from other CCR5 antagonists, though specific competing antagonists are not detailed.

Management Changes

Corporate Governance

Legal Proceedings

• **Securities Class Action Lawsuits**: Two consolidated putative class-action lawsuits allege false and misleading statements regarding leronlimab's viability for COVID-19, clinical trials, HIV BLA, and insider trading. Defendants' motions to dismiss were denied, with answers due August 25, 2025. The company denies wrongdoing and intends to vigorously defend.
• **Shareholder Derivative Lawsuits**: Multiple consolidated purported derivative lawsuits allege breach of fiduciary duties by former officers and directors for allowing false statements, failing to maintain oversight, waste of corporate assets, unjust enrichment, and insider trading. The company is named as a nominal defendant, denies wrongdoing, and intends to vigorously defend.
• **SEC and Department of Justice Investigations**: The company received subpoenas from the SEC and DOJ concerning leronlimab, public statements, communications with regulatory bodies and investors, and securities trading. Former CEO Nader Z. Pourhassan and former CRO CEO Kazem Kazempour were convicted by a federal jury in December 2024, with sentencing scheduled for September 2025. The company is cooperating fully, but the outcome and impact on its business, reputation, and financial condition are unpredictable and could be material.
• **Settlement of Amarex Dispute**: On July 2, 2024, the company settled with its former CRO, Amarex, resulting in a $12.0 million payment to CytoDyn (fully paid by June 2025), release of $6.5 million in cash collateral, and crediting of $14.0 million in claimed services, leading to a $25.0 million return of clinical expenses.
• **Investor Lawsuit Seeking Issuance of Additional Shares**: In January 2025, two former investors filed a lawsuit claiming they were entitled to more shares due to incorrect pricing in 2022 direct investments. The company views these claims as baseless and plans to vigorously defend itself.

Related Party Transactions

• Dr. Jacob Lalezari, the company's current CEO, owns Lalezari Medical Corp., dba Quest Clinical Research, which served as a clinical location for past COVID-19 clinical trials.
• Clinical Trial Agreements (CTAs) with Quest were negotiated by the company's former CRO (Amarex) prior to Dr. Lalezari's CEO appointment, with terms comparable to unrelated clinical locations.
• Since Dr. Lalezari became CEO, the company incurred approximately $11.4 thousand for services from Quest conducted by another principal investigator.
• As of May 31, 2025, the outstanding balance owed by the company to Quest was approximately $0.3 million.

Stakeholder Impact

• **Shareholders**: Face significant dilution from past and expected future equity/debt financing, high stock price volatility, and the common stock's 'penny stock' classification. No cash dividends are expected in the foreseeable future. The 'going concern' opinion and ongoing legal/regulatory issues pose substantial risks to investment value.
• **Employees**: The company's ability to recruit and retain skilled personnel is challenged by financial constraints and industry competition. Management changes, including the appointment of a new CFO, impact the organizational structure.
• **Patients**: Potential beneficiaries of leronlimab's development for serious conditions like mCRC, mTNBC, and GBM, offering new therapeutic options if approved.
• **Creditors/Suppliers**: Vendor relations are described as 'relatively accommodative' despite liquidity constraints, but the company's financial instability and reliance on capital raises present risks to timely payments. Convertible noteholders hold significant influence and redemption rights.
• **Regulatory Bodies**: The company is under close scrutiny from the SEC and FDA, with ongoing investigations and compliance requirements impacting operations and public perception.

Next Steps

• Continue the Phase II trial of leronlimab in patients with relapsed/refractory micro-satellite stable colorectal cancer (mCRC).
• Conduct additional studies exploring leronlimab and its therapeutic potential in other solid-tumor oncology indications, including metastatic Triple-Negative Breast Cancer (mTNBC).
• Continue work researching and developing a new or modified long-acting version of leronlimab.
• Prospectively confirm the retrospective observations in mTNBC.
• Conduct ongoing discussions with Key Opinion Leaders (KOLs) towards initiating a study in patients with mTNBC on an abbreviated timeline.
• Move forward with an investigator-initiated pilot study in a group of patients with recurrent Glioblastoma Multiforme (GBM) at two US academic medical centers.
• Seek additional funding through equity or debt offerings, licensing agreements, supply and distribution agreements, and strategic alliances.
• Former CEO Nader Z. Pourhassan and Kazem Kazempour are scheduled to be sentenced in September 2025.
• Defendants' answers to the second amended complaint in the securities class action lawsuit are due on August 25, 2025.

Key Dates

Recommendation

Despite a reported net income for the fiscal year, this was primarily due to a one-time legal settlement, masking continued operational losses and a severe liquidity crunch, as evidenced by the 'going concern' opinion. The company faces significant financial hurdles, including substantial debt obligations and the need for continuous capital raises, which will likely lead to further shareholder dilution. Ongoing SEC and DOJ investigations, including criminal convictions of former leadership, introduce considerable legal and reputational risk. While the clinical data for leronlimab in oncology, particularly the mTNBC survival outcomes and PD-L1 mechanism, are encouraging and the strategic pivot to oncology is positive, the company's financial instability and legal overhang make it a high-risk investment. A 'Hold' recommendation is appropriate for existing investors who might want to monitor the progress of clinical trials and the resolution of legal issues, given the potential upside if leronlimab achieves regulatory success in oncology, but 'Sell' is not warranted given the early positive clinical signals and strategic focus. New investors should exercise extreme caution due to the significant risks.

Keywords

CytoDyn, leronlimab, biotechnology, clinical-stage, oncology, colorectal cancer, triple-negative breast cancer, mCRC, mTNBC, CCR5, monoclonal antibody, clinical trials, FDA approval, drug development, financial health, SEC filing, 10-K, going concern, liquidity, legal proceedings, intellectual property, capital raise, PD-L1, immune checkpoint inhibitors, glioblastoma multiforme